Mouse models of thyroid cancer: Bridging pathogenesis and novel therapeutics.
作者： Yuchen Jin , Min Liu , Ri Sa , Hao Fu , Lin Cheng
DOI: 10.1016/J.CANLET.2019.09.017
关键词:
摘要: Due to a global increase in the incidence of thyroid cancer, numerous novel mouse models were established reveal cancer pathogenesis and test promising therapeutic strategies, necessitating comprehensive review translational medicine that covers (i) role research pathogenesis, (ii) preclinical testing potential anti-thyroid therapeutics. The present article aims to: describe current approaches for modeling provide insight into biology genetics cancers, (iii) offer guidance on use therapeutics settings. Based with involving RTK, RAS/RAF/MEK/ERK, PI3K/AKT/mTOR, SRC, JAK-STAT signaling pathways, inhibitors VEGFR, MEK, mTOR, STAT3 have been developed as drugs "bench-to-bedside" translation. In future, will be designed ''humanized" "patient-like," offering opportunities investigate through target screening based CRISPR/Cas system, new models, explore underlying mechanisms multi-omics.
sci-hub.se 参考文章(258)
E. J. Sherman, M. G. Fury, R. M. Tuttle, R. Ghossein, H. Stambuk, M. Baum, D. Lisa, Y. B. Su, A. Shaha, D. G. Pfister, Phase II study of depsipeptide (DEP) in radioiodine (RAI)-refractory metastatic nonmedullary thyroid carcinoma Journal of Clinical Oncology. ,vol. 27, pp. 6059- 6059 ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.6059
Lawrence S. Kirschner, Zahida Qamri, Suresh Kari, Amruta Ashtekar, Mouse models of thyroid cancer: A 2015 update Molecular and Cellular Endocrinology. ,vol. 421, pp. 18- 27 ,(2016) , 10.1016/J.MCE.2015.06.029
Han Lin, Xian Jiang, Huaqiang Zhu, Wenjing Jiang, Xuesong Dong, Haiquan Qiao, Xueying Sun, Hongchi Jiang, 2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma Tumor Biology. ,vol. 37, pp. 381- 391 ,(2016) , 10.1007/S13277-015-3816-1
Frauke Bentzien, Marcus Zuzow, Nathan Heald, Anna Gibson, Yongchang Shi, Leanne Goon, Peiwen Yu, Stefan Engst, Wentao Zhang, Donghui Huang, Lora Zhao, Valentina Vysotskaia, Felix Chu, Rajana Bautista, Belinda Cancilla, Peter Lamb, Alison H. Joly, F. Michael Yakes, In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Thyroid. ,vol. 23, pp. 1569- 1577 ,(2013) , 10.1089/THY.2013.0137
J. Bready, A. Polverino, J. Canon, R. Kendall, T. Osgood, A. Coxon, R. Radinsky, L. Wang, P. Hughes, J. Estrada, S. Kaufman, Anti-tumor activity of motesanib in a medullary thyroid cancer model. Journal of Endocrinological Investigation. ,vol. 35, pp. 181- 190 ,(2012) , 10.3275/7609
Steven A. Rosenberg, Vincent T. DeVita, Samuel Hellman, Cancer : Principles and Practice of Oncology ,(1982)
Rong Bu, Shahab Uddin, Maqbool Ahmed, Azhar R. Hussain, Saif Alsobhi, Tarek Amin, Abdurahman Al-Nuaim, Fouad Al-Dayel, Jehad Abubaker, Prashant Bavi, Khawla S. Al-Kuraya, c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell death. Molecular Medicine. ,vol. 18, pp. 167- 177 ,(2012) , 10.2119/MOLMED.2011.00238
Pierre Vanden Borre, David G. McFadden, Viswanath Gunda, Peter M. Sadow, Shohreh Varmeh, Maria Bernasconi, Tyler Jacks, Sareh Parangi, The Next Generation of Orthotopic Thyroid Cancer Models: Immunocompetent Orthotopic Mouse Models of BRAFV600E-Positive Papillary and Anaplastic Thyroid Carcinoma Thyroid. ,vol. 24, pp. 705- 714 ,(2014) , 10.1089/THY.2013.0483
Ying C. Henderson, Rafael Toro-Serra, Yunyun Chen, Junsun Ryu, Mitchell J. Frederick, Ge Zhou, Gary E. Gallick, Stephen Y. Lai, Gary L. Clayman, Src inhibitors in suppression of papillary thyroid carcinoma growth Head and Neck-journal for The Sciences and Specialties of The Head and Neck. ,vol. 36, pp. 375- 384 ,(2014) , 10.1002/HED.23316
Tarik Regad, Targeting RTK signaling pathways in cancer Cancers. ,vol. 7, pp. 1758- 1784 ,(2015) , 10.3390/CANCERS7030860